Coherus BioSciences, Inc.
High concentration formulations of adalimumab

Last updated:

Abstract:

The present invention relates to aqueous pharmaceutical compositions comprising a high concentration (i.e., greater than 50 milligrams per milliliter) of adalimumab (including antibody proteins considered or intended as "biosimilar" or "bio-better" variants of commercially available adalimumab) suitable for long-term storage, and methods of manufacture of the compositions; methods of their administration; and articles containing the same.

Status:
Grant
Type:

Utility

Filling date:

28 Oct 2016

Issue date:

25 Jan 2022